Kevin K C Liu

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi Synthetic approaches to the 2009 new drugs
    Kevin K C Liu
    Pfizer Inc, La Jolla, CA 92037, USA
    Bioorg Med Chem 19:1136-54. 2011
  2. doi Synthetic approaches to the 2010 new drugs
    Kevin K C Liu
    Pfizer Inc, La Jolla, CA 92037, USA
    Bioorg Med Chem 20:1155-74. 2012
  3. ncbi Synthetic approaches to the 2008 new drugs
    Kevin K C Liu
    Pfizer Inc, La Jolla, CA 92037, USA
    Mini Rev Med Chem 9:1655-75. 2009
  4. doi Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors
    Kevin K C Liu
    Pfizer Global Research and Development, Chemistry Department, 10770 Science Center Drive, La Jolla, CA 92120, USA
    Bioorg Med Chem Lett 21:1270-4. 2011
  5. ncbi Synthetic approaches to the 2006 new drugs
    Kevin K C Liu
    Pfizer Inc, La Jolla, CA 92037, USA
    Mini Rev Med Chem 7:1255-69. 2007
  6. doi 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
    Kevin K C Liu
    Pfizer Global Research and Development, Chemistry Department, La Jolla, CA 92120, USA
    Bioorg Med Chem Lett 20:6096-9. 2010
  7. doi Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity
    Kevin K C Liu
    Pfizer Global Research and Development, Chemistry Department, 10770 Science Center Drive, La Jolla, CA 92120, United States
    Bioorg Med Chem Lett 20:2365-9. 2010
  8. doi Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity
    Kevin K C Liu
    Pfizer Global Research and Development, Chemistry Department, 10770 Science Center Drive, La Jolla, CA 92120, United States
    Bioorg Med Chem Lett 20:266-71. 2010
  9. ncbi Synthetic approaches to the 2007 new drugs
    Kevin K C Liu
    Pfizer Inc, La Jolla, CA 92037, USA
    Mini Rev Med Chem 8:1526-48. 2008
  10. ncbi Synthetic approaches to the 2002 new drugs
    Jin Li
    Pfizer Global Research and Development, Pfizer Inc, Groton CT 06340, USA
    Mini Rev Med Chem 4:207-33. 2004

Detail Information

Publications18

  1. doi Synthetic approaches to the 2009 new drugs
    Kevin K C Liu
    Pfizer Inc, La Jolla, CA 92037, USA
    Bioorg Med Chem 19:1136-54. 2011
    ..These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the syntheses of 21 NCEs marketed in 2009...
  2. doi Synthetic approaches to the 2010 new drugs
    Kevin K C Liu
    Pfizer Inc, La Jolla, CA 92037, USA
    Bioorg Med Chem 20:1155-74. 2012
    ..These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010...
  3. ncbi Synthetic approaches to the 2008 new drugs
    Kevin K C Liu
    Pfizer Inc, La Jolla, CA 92037, USA
    Mini Rev Med Chem 9:1655-75. 2009
    ..These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the syntheses of 18 NCEs marketed in 2008...
  4. doi Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors
    Kevin K C Liu
    Pfizer Global Research and Development, Chemistry Department, 10770 Science Center Drive, La Jolla, CA 92120, USA
    Bioorg Med Chem Lett 21:1270-4. 2011
    ..In addition, a novel synthetic route was developed for these analogs...
  5. ncbi Synthetic approaches to the 2006 new drugs
    Kevin K C Liu
    Pfizer Inc, La Jolla, CA 92037, USA
    Mini Rev Med Chem 7:1255-69. 2007
    ..To these ends, this review covers the syntheses of 16 NCEs marketed in 2006...
  6. doi 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors
    Kevin K C Liu
    Pfizer Global Research and Development, Chemistry Department, La Jolla, CA 92120, USA
    Bioorg Med Chem Lett 20:6096-9. 2010
    ..This series of compounds were further optimized to improve their potency against PI3Kα and mTOR. Finally, orally active compounds with improved solubility and robust in vivo efficacy in tumor growth inhibition were identified as well...
  7. doi Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity
    Kevin K C Liu
    Pfizer Global Research and Development, Chemistry Department, 10770 Science Center Drive, La Jolla, CA 92120, United States
    Bioorg Med Chem Lett 20:2365-9. 2010
    ..After medicinal chemistry optimization and SAR studies, orally active proline amides with robust efficacy in a rodent food intake inhibition model were uncovered...
  8. doi Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity
    Kevin K C Liu
    Pfizer Global Research and Development, Chemistry Department, 10770 Science Center Drive, La Jolla, CA 92120, United States
    Bioorg Med Chem Lett 20:266-71. 2010
    ..Orally-active and selective compounds were identified with dose-responsive in vivo efficacy in our pre-clinical food intake model...
  9. ncbi Synthetic approaches to the 2007 new drugs
    Kevin K C Liu
    Pfizer Inc, La Jolla, CA 92037, USA
    Mini Rev Med Chem 8:1526-48. 2008
    ..These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the syntheses of 19 NCEs marketed in 2007...
  10. ncbi Synthetic approaches to the 2002 new drugs
    Jin Li
    Pfizer Global Research and Development, Pfizer Inc, Groton CT 06340, USA
    Mini Rev Med Chem 4:207-33. 2004
    ..Therefore, it is important to be acquainted with these new structures as well as their syntheses. To these ends, this review covers the syntheses of 28 NCEs marketed in 2002...
  11. ncbi Synthetic approaches to the 2005 new drugs
    Subas M Sakya
    Pfizer Global Research and Development, Pfizer, Inc, Groton, CT 06340, USA
    Mini Rev Med Chem 7:429-50. 2007
    ..To these ends, this review covers the syntheses of 22 NCEs marketed in 2005...
  12. ncbi Synthetic approaches to the 2004 new drugs
    Jin Li
    Pfizer Global Research and Development, Pfizer Inc, Groton CT 06340, USA
    Mini Rev Med Chem 5:1133-44. 2005
    ..In addition, these new chemical entities (NCEs) not only provide insights into molecular recognition, but also serve as leads for designing future drugs. To this end, this review covers the syntheses of 12 NCEs marketed in 2004...
  13. doi Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatme
    Amit S Kalgutkar
    Pharmacokinetics, Dynamics and Metabolism Department and Department of Medicinal Chemistry, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Chem Res Toxicol 23:1115-26. 2010
    ..Herein, the collective findings from our discovery efforts in the CaSR program, which include the incorporation of appropriate derisking steps when dealing with RM issues are summarized...
  14. doi Design and synthesis of pyridazinone-based 5-HT(2C) agonists
    Charlotte M N Allerton
    Department of Discovery Chemistry, Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT139NJ, UK
    Bioorg Med Chem Lett 19:5791-5. 2009
    ..This compound displayed good in vivo efficacy in pre-clinical models of stress urinary incontinence, despite having physiochemical properties commensurate with impaired CNS penetration...
  15. ncbi Synthetic approaches to the 2003 new drugs
    Kevin K C Liu
    Pfizer Global Research and Development, Pfizer Inc, Groton, CT 06340, USA
    Mini Rev Med Chem 4:1105-25. 2004
    ..To these ends, this review covers the syntheses of 23 NCEs marketed in 2003...
  16. doi Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors
    Kevin K C Liu
    Pfizer Global Research and Development, Chemistry Department, La Jolla, CA 92120, USA
    Bioorg Med Chem Lett 22:5114-7. 2012
    ..PF-05139962 was identified with excellent mTOR biochemical inhibition, cellular potency, kinase selectivity and in vitro ADME properties...
  17. doi Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants
    Hengmiao Cheng
    La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States
    J Med Chem 59:2005-24. 2016
    ....
  18. doi Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists
    Mary T Didiuk
    Pfizer Global Research and Development, Groton, CT 06340, United States
    Bioorg Med Chem Lett 19:4555-9. 2009
    ..Orally-active compounds were identified which displayed the desired animal pharmacology (rapid and transient stimulation of parathyroid hormone) essential for bone anabolic effects...